In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

Robin Patel, Mark S. Rouse, Kerryl E. Piper, James M. Steckelberg

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by ≤ 1, ≤ 2, or ≤ 0.25 μg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 μg/ml of GAR-936 and 0.25 μg/ml of quinupristin/dalfopristin. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume38
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Penicillins
Anti-Infective Agents
Genes
Vancomycin-Resistant Enterococci
tigecycline
In Vitro Techniques

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. / Patel, Robin; Rouse, Mark S.; Piper, Kerryl E.; Steckelberg, James M.

In: Diagnostic Microbiology and Infectious Disease, Vol. 38, No. 3, 2000, p. 177-179.

Research output: Contribution to journalArticle

@article{21c0bdecf0b64c1a88f1c9dde91653ed,
title = "In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae",
abstract = "We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by ≤ 1, ≤ 2, or ≤ 0.25 μg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 μg/ml of GAR-936 and 0.25 μg/ml of quinupristin/dalfopristin. (C) 2000 Elsevier Science Inc.",
author = "Robin Patel and Rouse, {Mark S.} and Piper, {Kerryl E.} and Steckelberg, {James M.}",
year = "2000",
doi = "10.1016/S0732-8893(00)00193-0",
language = "English (US)",
volume = "38",
pages = "177--179",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

AU - Patel, Robin

AU - Rouse, Mark S.

AU - Piper, Kerryl E.

AU - Steckelberg, James M.

PY - 2000

Y1 - 2000

N2 - We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by ≤ 1, ≤ 2, or ≤ 0.25 μg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 μg/ml of GAR-936 and 0.25 μg/ml of quinupristin/dalfopristin. (C) 2000 Elsevier Science Inc.

AB - We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by ≤ 1, ≤ 2, or ≤ 0.25 μg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 μg/ml of GAR-936 and 0.25 μg/ml of quinupristin/dalfopristin. (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033667340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033667340&partnerID=8YFLogxK

U2 - 10.1016/S0732-8893(00)00193-0

DO - 10.1016/S0732-8893(00)00193-0

M3 - Article

VL - 38

SP - 177

EP - 179

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -